ESC 365 - Combination therapy with macitentan and phosphodiesterase type-5 inhibitor (PDE5i) in pulmonary arterial hypertension (PAH): real-world data from OPUS and OrPHeUS

ESC Premium Access

Combination therapy with macitentan and phosphodiesterase type-5 inhibitor (PDE5i) in pulmonary arterial hypertension (PAH): real-world data from OPUS and OrPHeUS

Session: Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure ePosters

Topic: Pulmonary Hypertension

Speaker: Professor V. McLaughlin (Ann Arbor, US)

Event: ESC Congress 2020

Congress Presentation

Add to my library

About the speaker

Professor Vallerie McLaughlin

University of Michigan, Ann Arbor (United States of America)

5 presentations

0 follower

62 more presentations in this session

Shift in transcriptional landscape of human right ventricle in chronic thromboembolic pulmonary arterial hypertension

Speaker: Ms L. Jafari (Giessen, DE)

Relationship between right ventricular diastolic dysfunction, right atrial phasic function and ventricular filling in pulmonary arterial hypertension

Speaker: Mr J. Wessels (Amsterdam, NL)

Aetiology of sarcoidosis-associated pulmonary hypertension

Speaker: Mr H. Mathijssen (Nieuwegein, NL)

Pre-operative pulmonary artery pulsatility index does not predict mortality post cardiac transplantation but PVR is a prognostic tool in LVAD-bridged patients.

Speaker: Doctor N. Bart (Sydney, AU)

Venous lactate predicts adverse outcomes in normotensive pulmonary embolism

Speaker: Doctor M. Ebner (Berlin, DE)

Access the full session

Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure ePosters

Speakers: Professor V. McLaughlin, Ms L. Jafari, Mr J. Wessels, Mr H. Mathijssen, Doctor N. Bart...

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources